Nacuity Pharmaceuticals, Inc. (Nacuity) announces that it has entered into an agreement with Johns Hopkins University (JHU) providing Nacuity with an exclusive worldwide license to the intellectual property (IP) underlying certain U.S. and foreign patent applications that Nacuity has filed in collaboration with the Johns Hopkins Wilmer Eye Institute. Read more...
Nacuity Pharmaceuticals is featured in an article in The Adelaide Review as one of the pharmaceutical companies taking advantage of the financial and regulatory incentives provided by Adelaide, Australia, to bring clinical trials to their city.
September 27, 2017
Nacuity Pharmaceuticals CEO Halden Conner presented the company’s emerging drug N-Acetylcysteine Amide (NACA) at The Foundation Fighting Blindness' "Investing in Cures Summit" in Chicago, Illinois.
January 19, 2017
This post from the The Foundation Fighting Blindness' blog "Eye on the Cure" describes its investment in Nacuity Pharmaceuticals to advance RP treatment.
January 18, 2017
The Foundation Fighting Blindness, the leading charitable institution driving research to provide treatments for people affected by RP and AMD, issues a press release announcing its technical and financial support of Nacuity Pharmaceuticals.